We use genetically engineered mouse models (GEMM) of pancreatic cancer, allowing deletion of WT Kras, in combination with preclinical trialing of clinically relevant target therapeutic approaches to carefully dissect each of these features. This evidence concerns the gene KRAS and pancreatic neoplasm.